Glenmark Consumer Care sales rise 28% as Candid and Scalpe grow over 30%

Glenmark Pharmaceuticals reported Q1 FY27 consumer-care primary sales of ₹155.8 crore, up 28% year-on-year, led by over-30% growth in Candid and Scalpe. India formulation sales rose 15.5% to ₹1,432.1 crore.

— Source publishedFri, 31 Jul, 2026, 21:13 IST·First seen Fri, 31 Jul, 2026, 21:22 IST·Source CNBC-TV18 · Companies

What happened

Glenmark Pharmaceuticals · Glenmark’s Q1 FY27 profit rose 930% to ₹483 crore as India formulation sales grew 15.5% and consumer-care sales climbed 28%. Flagship

Key facts

  • Consolidated net profit: ₹483 crore, up 930% YoY from ₹47 crore
  • Revenue: ₹4,018 crore, up 23% YoY
  • EBITDA: ₹805 crore, up 39% YoY
  • EBITDA margin: 20%, versus 17.8%
  • India formulation sales: ₹1,432.1 crore, up 15.5% YoY
  • Glenmark Consumer Care primary sales: ₹155.8 crore, up 28% YoY
  • North America revenue: ₹1,097.4 crore, up 41.1% YoY
  • Europe revenue: ₹747.2 crore, up 11.9% YoY
  • Emerging Markets revenue: ₹730.4 crore, up 27.7% YoY
  • India pharma market share: 2.37%; rank: 13

Why this matters

The strength of Candid and Scalpe reinforces Glenmark’s attractiveness as a consumer-health platform, with adjacencies in dermatology, hygiene and scalp care offering logical partnership or bolt-on targets.

What to watch

  • Secondary sales growth versus the reported 28% primary-sales increase.
  • Distributor inventory days, returns and reorder frequency for Candid and Scalpe.
  • Consumer-care gross margin and advertising/promotion expense as a share of sales.
  • Market-share movement in anti-fungal and scalp-care categories.
  • Modern-trade and e-commerce contribution, availability metrics and stock-out rates.
  • Whether India formulations continue to outgrow the domestic pharma market after the reported 15.5% increase.
  • Increase pharmacy and general-trade availability for Candid and Scalpe in underpenetrated cities and rural clusters.
  • Deploy incremental advertising and dermatologist/pharmacist-led education to convert brand awareness into repeat purchase.
  • Expand modern-trade and e-commerce packs, including regimen or value bundles for anti-fungal and scalp-care use cases.
  • Use the stronger consumer-care base to cross-sell adjacent OTC, hygiene and personal-care products while monitoring channel inventory tightly.